Emerging Novel Therapies for the Treatment of Psoriasis: A Narrative Review

Le résumé fourni par la source

Psoriasis is a chronic autoimmune and autoinflammatory disorder defined by abnormal skin cell turnover and inflammation, resulting in the formation of plaques on the skin. Although biologic therapies targeting interleukin (IL)-17 and IL-23 have significantly improved the treatment landscape for moderate-to-severe psoriasis, they are not effective for all patients. This highlights the need for additional therapeutic strategies. In recent years, exploring novel treatment avenues such as targeting IL-21, small nucleolar RNA (snoRNA) Snora73, the gut microbiome, and natural remedies have shown increasing promise in managing psoriasis. Interleukin-21 is a cytokine that plays a critical role in the differentiation and function of Th17 cells, which are central to the pathogenesis of psoriasis. Recent studies have demonstrated that neutralizing IL-21 with specific antibodies can help restore immune homeostasis, reducing disease severity and improving patient outcomes. Targeting IL-21 may be particularly beneficial for patients resistant to conventional therapies like IL-17 and IL-23 inhibitors. In addition to IL-21, snoRNA Snora73 has emerged as a novel target for psoriasis treatment. Snora73 regulates cell proliferation by interacting with miR-3074-5p and pre-B-cell leukemia homeobox 1 (PBX1), promoting abnormal cell turnover in psoriasis. The gut microbiome is increasingly recognized for its role in autoimmune diseases, including psoriasis. Imbalances in the microbiome have been linked to disease exacerbation, triggering systemic inflammation and altering immune responses. Moreover, various natural treatments have gained attention for their anti-inflammatory properties. These natural therapies could serve as adjuncts to existing treatments, offering a complementary approach that minimizes side effects while improving patient outcomes. Targeting IL-21, Snora73, and the gut microbiome, as well as utilizing natural treatments, may provide new opportunities for more effective, personalized management of psoriasis.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.